Fluctuating weakness: clue in the eyes!

Amrit Kaur,1 Chakshu Chaudhry,1 Aditi Mehta,2 Anupriya Kaur1

DESCRIPTION
A 9-year-old girl presented with a history of increased fatigability and generalised weakness since past 2 months. Her parents told that around 8 years of age, she had become very sick with severe respiratory distress requiring hospitalisation and ventilation for 7 days after which she improved to her usual state of health. On repeated questioning, the parents only remembered that she was otherwise normal but would tire out easily and not be as physically active as other children of her age group.

She was born out of a consanguineous marriage with uneventful neonatal period and showed normal gain of various developmental milestones. Family belonged to the state of Jammu and Kashmir, in Northern India. There was no family history of similar complaints. On examination, her weight and height were 14 kg and 115 cm, respectively, (less than 3rd centile by Indian Academy of Pediatrics charts) suggesting acute on chronic malnutrition. There was no pallor, pedal oedema or abnormal heart sounds. She had elongated expressionless face with bilateral symmetrical ptosis (apparently unnoticed by parents) (figure 1). Motor examination showed power of grade 4/5 at shoulder and hip joints suggestive of mild proximal weakness. The deep tendon reflexes were preserved. On careful observation, we found her to be using neck movements more than eye while following objects, with neck being kept slightly extended. This led us to re-examine her which showed some limitation of eyeball movements towards the extremes in all directions of gaze. Sensory system examination was unremarkable. There were no contractures, tongue fasciculations, myotonia and cerebellar signs.

Neuromuscular disorders with involvement of ocular muscles such as moebius syndrome, mitochondrial myopathies or myasthenia were considered as possibilities. As the weakness appeared to be fluctuating in nature, myasthenia seemed likely. An ophthalmology consultation revealed that her Cogan lid test was positive. It was elicited by having the patient look in downgaze followed by up gaze. As the affected eye saccades up, upper lid having the patient look in downgaze followed by her Cogan lid test was positive. It was elicited by

investigations showed creatine phosphokinase to be 47 U/L (normal range 26–180 U/L) and lactate to be 0.8 mmol/L (normal range <2 mmol/L). Repetitive nerve stimulation test at 3 Hz was suggestive of decremental response and improvement with neostigmine. Acetylcholine receptor antibody and anti-Musk antibody were absent. Exome sequencing showed a pathogenic homozygous indel variant in exon 2 of CHRNE gene (chr 17:4805974 T>T) by insertion of guanine at 130 coding position (c.130_131insG) which is predicted to cause a frameshift and consequent premature truncation of the protein (p.Glu44fs) confirming presence of congenital myasthenic syndrome (CMS) 4B (fast channel) or 4C (acetylcholine receptor deficiency). The child was started on oral pyridostigmine and is showing some signs of improvement.

CMSs comprise of phenotypically and genetically heterogenous diseases caused due to neuromuscular transmission dysfunction. Till date, 32 genes causing CMS have been described. Although named congenital, disease onset may be in infancy, childhood or rarely in adolescence. Phenotypically various subtypes share fatigability and weakness as common features.

CHRNE gene mutations and in particular the variant found in our child has been found at a high frequency (around 30%) in patients of CMS in Brazilian and Spanish populations. Ophthalmoplegia as seen in our child is a universal finding with CHRNE gene mutations and the disease appears to follow a relatively benign natural course in patients with c.130dupG.

CMS are one of the rare examples of treatable genetic neuromuscular diseases. Although pyridostigmine is effective for CHRNE gene mutation subtype of CMS, in some other subtypes it can make symptoms worse. Hence, genetic testing not
only confirms the clinical diagnosis but is also required for the
correct treatment approach in CMS.  

Patient’s perspective

We were really anxious, since our daughter was requiring
multiple hospital admissions. Last time had to be ventilated;
however, we were not clear about the underlying problem. After
starting pyridostigmine she is showing signs of improvement and
did not require any further hospitalisation.

Learning points

- Fluctuating weakness especially in young children is likely to
  be missed.
- One should consider myasthenia, hypohyperkalemic periodic
  paralysis, metabolic myopathies and toxin exposures in such
  cases.
- Congenital myasthenic syndromes (CMSs) though named
  congenital have variable age of onset from birth to
  adulthood.
- CMSs are one of the rare examples of a treatable genetic
  neuromuscular disease, and therefore receiving a correct
  genetic diagnosis allows patients to be started on effective
  therapy.

Acknowledgements

We are thankful to the patient’s family for permitting us to
publish patient details and photographs.

Contributors

Am K: patient management, literature review and manuscript
preparation, CC: patient management, follow up and literature review, AM: literature
review and patient management, An K: Clinician in-charge, critical review of the
manuscript and final approval of the version to be published.

Funding

The authors have not declared a specific grant for this research from any
funding agency in the public, commercial or not-for-profit sectors.

Competing interests

None declared.

Patient consent for publication

Parental/guardian consent obtained.

Provenance and peer review

Not commissioned; externally peer reviewed.

ORCID IDs

Amrit Kaur http://orcid.org/0000-0001-5751-6022
Chakshu Chaudhry http://orcid.org/0000-0002-0080-2172
Aditi Mehta http://orcid.org/0000-0003-0891-8169

REFERENCES

1 Finsterer J. Congenital myasthenic syndromes. Orphanet J Rare Dis 2019;14:57.
2 Estephan EdeP, Sobreira CFdaR, Dos Santos ACL, et al. A common CHRNE mutation in
3 Natera-de Benito D, Töpf A, Vilchez JJ, et al. Molecular characterization of congenital
4 Engel AG, Shen X-M, Selcen D, et al. Congenital myasthenic syndromes: pathogenesis,
syndromes: systematic review and steps towards a treatabolome. Emerg Top Life Sci